Jai Grewal, MD

NSPC Spine & Brain Surgery
Long Island, NY Clinical Neuro-Oncologist Executive Board Member American Cancer Society

Dr. Grewal (NSPC Brain and Spine Surgery, Rockville Center, NY) is a board certified neuro-oncologist who completed his neuro-oncology fellowship at the MD Anderson Cancer Center in Houston, Texas. Following medical school, he completed an internal medicine internship at Griffin Hospital in Connecticut, which is affiliated with Yale University. He then finished a neurology residency at the University of Texas, Southwestern. His clinical practice includes management of patients with primary and metastatic tumors of the brain and spine. He received The Robert Bernstein Humanitarian Award as well as is one of the Castle Connolly Top Doctors. Dr. Grewal has an interest in utilizing multi-modality treatment options, including surgical options, limited-field radiotherapy, stereotactic radiosurgery, as well as standard and experimental chemotherapy. In addition to the treatment of tumors, he has an interest in developing strategies to preserve quality of life.

AR-67 has the potential to deliver the efficacy of Camptothecins with significantly less gastrointestinal and hematological toxicity than Irinotecan. That could be a game changer for patients with gastrointestinal cancers.
Dr. Gerard Blobe, MD, PhD.Duke University School of Medicine.
AR–67 is a next generation camptothecin optimized for fewer side effects and blood-brain-barrier penetration. In glioblastoma patients treated with AR-67 on a clinical trial at our center, we saw encouraging outcomes and tumor shrinkage. AR-67 was extremely well tolerated. I believe AR-67 represents a novel approach in treating this devastating disease.
Dr. Jai Grewal, MD.NSPC Brain and Spine Surgery, NY

References

1. Novel silatecan displays high lipophilicity, improved blood stability and potent
anticancer activity. Bom D, et al J Med Chem 2000; 43:3970-3980

2. Silatecan DB-67 is a novel DNA Topo-1 targeted radiation sensitizer: Chen AY. Mol
Cancer Ther 2005; 4(2): 317-24.

3. Phase I study publication: Arnold SM, et al. Clin Cancer Res. 2010;6:673-680

4. Phase II study publication (abstract): Kumthekar P, et al. SNO 2019. Poster ACTR-40,
published in Neuro-Oncology(https://academic.oup.com/neuro-oncology)

5. Ubiquitin-dependent Destruction of Topoisomerase I Is
Stimulated by the Antitumor Drug Camptothecin*, Desai et al. The Journal of Biological Chemistry, Vol. 272, No. 39, Issue of September 26, pp. 24159–24164, 1997.  https://www.jbc.org

6. Metabolic Pathways of the Camptothecin Analog AR-67, Horn et al. Drug Metabolism and Disposition, Vol. 39, No. 4, 37390/3672838, 2011. https://dmd.aspetjournals.org